

Supplementary Table 1. Participants' characteristics according to SWV values

Characteristic	Participants with increased SWV (n=32)	Participants with decreased SWV (n=35)	P-value
Age (year)	63.2±10.6	61.4±9.7	0.480
Sex (male:female)	20:12	20:15	0.658
Serum CEA level	34.4 (7.7–319)	24.7 (5.8–181)	0.585
Primary site of colorectal cancer			0.732
Ascending colon	9 (28.2)	6 (17.2)	
Descending colon	0	1 (2.9)	
Sigmoid colon	15 (46.9)	16 (45.7)	
Rectosigmoid colon	2 (6.2)	3 (8.6)	
Rectum	6 (18.8)	9 (25.7)	
Resection of primary colorectal cancer			0.071
Yes	22 (68.8)	31 (88.6)	
No	10 (31.2)	4 (11.4)	
Nodal metastasis of primary colorectal cancer			0.865
Yes	26 (81.2)	29 (82.9)	
No	6 (18.8)	6 (17.1)	
KRAS mutation			0.247
Yes	8 (53.3)	9 (34.6)	
No	7 (46.7)	17 (65.4)	
Timing of CRLM			0.200
Synchronous to primary colorectal cancer	31 (96.9)	31 (88.6)	
Metachronous to primary colorectal cancer	1 (3.1)	4 (11.4)	
Size of CRLM where ARFI was performed (cm)	3.3 (2.2–5.2)	3.9 (2.0–5.1)	0.960
No. of CRLMs			0.182
1	1 (3.1)	3 (8.6)	
2	2 (6.2)	8 (22.9)	
3	3 (9.4)	1 (2.9)	
4	3 (9.4)	1 (2.9)	
≥5	23 (71.9)	22 (62.9)	
Location of CRLM where ARFI was performed			0.774
Right lobe	28 (87.5)	30 (85.7)	
Left lobe	4 (12.5)	5 (14.3)	
Measurement depth of SWV (cm)	4.8±1.3	4.4±1.1	0.279
Confirmative method for CRLM			0.189
Histopathology	18 (56.2)	14 (40.0)	
Clinical features	14 (43.8)	21 (60.0)	
Chemotherapy regimen			0.210
FOLFOX or FOLFIRI	7 (21.9)	13 (37.1)	
FOLFOX or FOLFIRI+bevacizumab	15 (46.8)	8 (22.9)	
FOLFOX or FOLFIRI+cetuximab	10 (31.3)	14 (40.0)	
Treatment response			<0.001
Responder	8 (25.0)	26 (74.3)	
CR	0	1 (2.9)	
PR	8 (25.0)	25 (71.4)	
Non-responder	24 (75.0)	9 (25.7)	
SD	22 (68.8)	9 (25.7)	
PD	2 (6.2)	0	

Values are presented as mean±standard deviation, median (IQR), or number (%).

SWV, shear-wave velocity; CEA, carcinoembryonic antigen; KRAS, Kirsten rat sarcoma virus; CRLM, colorectal liver metastasis; ARFI, acoustic radiation force impulse; FOLFOX, 5-fluorouracil, leucovorin, and oxaliplatin; FOLFIRI, 5-fluorouracil, leucovorin, and irinotecan; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.